CoChat
Sign Up
Cited by 89

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo

Tai, Leon M., Koster, Kevin P., Luo, Jia, Lee, Sue H., Wang, Yue-ting, Collins, Nicole C., Ben Aissa, Manel, Thatcher, Gregory R.J., LaDu, Mary Jo·2014·Journal of Biological Chemistry
DOI 10.1074/jbc.m114.600833
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m114.600833

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ApoE4 does not clear plaques or soluble Aβ as well as apoE3.

    “studies have demonstrated that apoE4 does not clear plaques or soluble Aβ as well as apoE3 [45, 46].”

    From Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation (2023) · cites this paper as [46]

    The RXR Agonist Mechanism of Action section (page unavailable) explicitly says soluble Aβ clearance is lower with apoE4 than with apoE3. The Collective Data Analysis section (page unavailable) reports more insoluble Aβ in E4FAD than E3FAD mice, but does not establish that apoE4 clears existing plaques less effectively. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Cholesterol transport to apoE4-lipoproteins was not increased by AVAS.

    “As measured by Western blot and normalized to β-actin (Fig. 7e), ABCA1 levels did not change with AVAS treatment, evidence that cholesterol transport to the apoE4-lipoproteins was not increased [52].”

    From Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation (2023) · cites this paper as [52]

    The RXR Agonist Treatment Protocols section describes treatment with bexarotene (Bex) or LG100268, not AVAS. The E4FAD hippocampus results report increased apoE4 lipoprotein association with those agonists, but they do not establish what happens with AVAS. Searches for AVAS treatment and AVAS-related cholesterol transport found no passage addressing the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

  • Severe hepatomegaly is associated with RXR agonism due to induction of hepatic lipogenic pathways by SREBP1C.

    “However, severe hepatomegaly is associated with RXR agonism due to an induction of hepatic lipogenic pathways by sterol-regulatory element-binding protein 1C (SREBP1C) [52, 53].”

    From Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation (2023) · cites this paper as [52]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. Thies, 2013, 2013 Alzheimer's disease facts and figures, Alzheimers Dement, 9, 208, 10.1016/j.jalz.2013.02.003 · DOI
  2. Lue, 1999, Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease, Am. J. Pathol, 155, 853, 10.1016/S0002-9440(10)65184-X · DOI · Paper page
  3. McLean, 1999, Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease, Ann. Neurol, 46, 860, 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M · DOI
  4. Jin, 2011, Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration, Proc. Natl. Acad. Sci. U.S.A, 108, 5819, 10.1073/pnas.1017033108 · DOI · Paper page
  5. Kuo, 1996, Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains, J. Biol. Chem, 271, 4077, 10.1074/jbc.271.8.4077 · DOI · Paper page
  6. Selkoe, 2011, Resolving controversies on the path to Alzheimer's therapeutics, Nat. Med, 17, 1060, 10.1038/nm.2460 · DOI · Paper page
  7. Karran, 2014, Antiamyloid therapy for Alzheimer's disease–are we on the right road?, N. Engl. J. Med, 370, 377, 10.1056/NEJMe1313943 · DOI · Paper page
  8. Mikulca, 2014, Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches, J. Clin. Pharm. Ther, 39, 25, 10.1111/jcpt.12112 · DOI
  9. LaClair, 2013, Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice, Mol. Neurodegener, 8, 18, 10.1186/1750-1326-8-18 · DOI · Paper page
  10. Price, 2013, Comment on apoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models, Science, 340, 10.1126/science.1234089 · DOI · Paper page
  11. Yu, 2010, Proposed mechanism for lipoprotein remodelling in the brain, Biochim. Biophys. Acta, 1801, 819, 10.1016/j.bbalip.2010.05.001 · DOI
  12. Hirsch-Reinshagen, 2004, Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain, J. Biol. Chem, 279, 41197, 10.1074/jbc.M407962200 · DOI · Paper page
  13. Wahrle, 2004, ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE, J. Biol. Chem, 279, 40987, 10.1074/jbc.M407963200 · DOI · Paper page
  14. Wahrle, 2005, Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease, J. Biol. Chem, 280, 43236, 10.1074/jbc.M508780200 · DOI · Paper page
  15. Zelcer, 2007, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors, Proc. Natl. Acad. Sci. U.S.A, 104, 10601, 10.1073/pnas.0701096104 · DOI · Paper page
  16. Reitz, 2010, Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia, J. Alzheimers Dis, 19, 229, 10.3233/JAD-2010-1255 · DOI
  17. Leoni, 2011, The effect of apolipoprotein E (apoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease, Clin. Chem. Lab. Med, 49, 375, 10.1515/CCLM.2011.088 · DOI
  18. Qiu, 2013, Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele, J. Alzheimers Dis, 37, 421, 10.3233/JAD-130716 · DOI
  19. Farlow, 1998, Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease, Neurology, 50, 669, 10.1212/WNL.50.3.669 · DOI
  20. Risner, 2006, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease, Pharmacogenomics J, 6, 246, 10.1038/sj.tpj.6500369 · DOI · Paper page
  21. Tai, 2014, Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk, Mol. Neurodegener, 9, 2, 10.1186/1750-1326-9-2 · DOI · Paper page
  22. Tai, 2011, Introducing human APOE into Aβ transgenic mouse models, Int. J. Alzheimers Dis, 2011, 810981, 10.4061/2011/810981 · DOI · Paper page
  23. Boehm-Cagan, 2014, Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene, J. Neurosci, 34, 7293, 10.1523/JNEUROSCI.5198-13.2014 · DOI · Paper page
  24. Torino, 2013, Thyroid dysfunction as an unintended side effect of anticancer drugs, Thyroid, 23, 1345, 10.1089/thy.2013.0241 · DOI · Paper page
  25. Sherman, 2003, Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma, Clin. Lymphoma, 3, 249, 10.3816/CLM.2003.n.006 · DOI
  26. Liu, 2002, Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat, Endocrinology, 143, 2880, 10.1210/endo.143.8.8930 · DOI
  27. de Vries-van der Weij, 2009, Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein, Endocrinology, 150, 2368, 10.1210/en.2008-1540 · DOI
  28. Boehm, 1995, Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells, J. Med. Chem, 38, 3146, 10.1021/jm00016a018 · DOI
  29. Jurutka, 2013, J. Med. Chem, 56, 8432, 10.1021/jm4008517 · DOI
  30. Wang, 2006, Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide, Mol. Cancer Ther, 5, 1060, 10.1158/1535-7163.MCT-05-0322 · DOI
  31. de la Monte, 2014, Relationships between diabetes and cognitive impairment, Endocrinol. Metab. Clin. North Am, 43, 245, 10.1016/j.ecl.2013.09.006 · DOI
  32. Weissenborn, 2005, Neurological and neuropsychiatric syndromes associated with liver disease, AIDS, 19, S93, 10.1097/01.aids.0000192076.03443.6d · DOI
  33. Lewis, 2003, The neurology of liver failure, QJM, 96, 623, 10.1093/qjmed/hcg110 · DOI
  34. Sonneville, 2013, Understanding brain dysfunction in sepsis, Ann. Inten. Care, 3, 15, 10.1186/2110-5820-3-15 · DOI
  35. Faul, 2001, Synthesis of novel retinoid X receptor-selective retinoids, J. Org. Chem, 66, 5772, 10.1021/jo0103064 · DOI
  36. Fryer, 2005, Human apolipoprotein E4 alters the amyloid-β 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model, J. Neurosci, 25, 2803, 10.1523/JNEUROSCI.5170-04.2005 · DOI · Paper page
  37. Overk, 2011, A novel approach for long term oral drug administration in animal research, J. Neurosci. Methods, 195, 194, 10.1016/j.jneumeth.2010.12.009 · DOI
  38. Janakiram, 2012, Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice, Neoplasia, 14, 159, 10.1593/neo.111440 · DOI
  39. Overk, 2012, Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice, Neurobiol. Dis, 45, 479, 10.1016/j.nbd.2011.08.035 · DOI
  40. Howell, 2001, Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors, Drug Metab. Dispos, 29, 990
  41. Wu, 2002, Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069, Cancer Epidemiol. Biomarkers Prev, 11, 467
  42. Youmans, 2011, Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations, J. Neurosci. Methods, 196, 51, 10.1016/j.jneumeth.2010.12.025 · DOI · Paper page
  43. Sultana, 2010, J. Neurosci. Res, 88, 469, 10.1002/jnr.22227 · DOI
  44. Koffie, 2009, Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques, Proc. Natl. Acad. Sci. U.S.A, 106, 4012, 10.1073/pnas.0811698106 · DOI · Paper page
  45. Li, 2012, Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms, J. Biol. Chem, 287, 44593, 10.1074/jbc.M112.420224 · DOI
  46. Verghese, 2013, ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions, Proc. Natl. Acad. Sci. U.S.A, 110, E1807, 10.1073/pnas.1220484110 · DOI · Paper page
  47. Ly, 2013, Binding of apolipoprotein E inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy, J. Biol. Chem, 288, 11628, 10.1074/jbc.M112.411900 · DOI
  48. Larson, 2012, Soluble Aβ oligomer production and toxicity, J. Neurochem, 120, 125, 10.1111/j.1471-4159.2011.07478.x · DOI · Paper page
  49. Fowler, 2014, Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease, J. Neurosci, 34, 7871, 10.1523/JNEUROSCI.0572-14.2014 · DOI
  50. Hong, 2011, Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation, J. Neurosci, 31, 15861, 10.1523/JNEUROSCI.3272-11.2011 · DOI · Paper page
  51. Wong, 2006, SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR, Biochem. J, 400, 485, 10.1042/BJ20060914 · DOI · Paper page
  52. Mohamed, 2012, β-Amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage, J. Neurosci, 32, 6490, 10.1523/JNEUROSCI.0630-12.2012 · DOI
  53. Lim, 2014, The involvement of lipids in Alzheimer's disease, J. Genet. Genomics, 41, 261, 10.1016/j.jgg.2014.04.003 · DOI
  54. Altmann, 2014, Sex modifies the APOE-related risk of developing Alzheimer disease, Ann. Neurol, 75, 563, 10.1002/ana.24135 · DOI · Paper page
  55. Bretsky, 1999, Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease, Alzheimer Dis. Assoc. Disord, 13, 216, 10.1097/00002093-199910000-00007 · DOI
  56. Payami, 1996, Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women, Am. J. Hum. Genet, 58, 803
  57. Jacobs, 2013, Accelerated cell aging in female APOE-ϵ4 carriers: implications for hormone therapy use, PLoS One, 8, e54713, 10.1371/journal.pone.0054713 · DOI
  58. Kunzler, 2014, APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice, Neurosci. Lett, 560, 131, 10.1016/j.neulet.2013.12.032 · DOI
  59. Pérez, 2012, Modulation of RXR function through ligand design, Biochim. Biophys. Acta, 1821, 57, 10.1016/j.bbalip.2011.04.003 · DOI · Paper page
  60. Scarisbrick, 2013, U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma, Br. J. Dermatol, 168, 192, 10.1111/bjd.12042 · DOI
  61. Väkevä, 2012, Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland, Acta Derm. Venereol, 92, 258, 10.2340/00015555-1359 · DOI
  62. Erbas, 2014, Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogues (exenatide) on cognitive function in hepatosteatosis, Scientific World J, 2014, 946265, 10.1155/2014/946265 · DOI
  63. Elliott, 2013, Functional impairment in alcoholic liver disease and nonalcoholic fatty liver disease is significant and persists over 3 years of follow-up, Digest. Dis. Sci, 58, 2383, 10.1007/s10620-013-2657-2 · DOI

Cited by

Sorted by citations

Metadata

Authors
Tai, L. M., Koster, K. P., Luo, J., Lee, S. H., Wang, Y.-T., Collins, N. C., Ben Aissa, M., Thatcher, G. R. J., & LaDu, M. J.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2014-10
Volume
289
Issue
44
Pages
30538-30555
ISSN
0021-9258
DOI
10.1074/jbc.m114.600833
Cited by
89
References
24
Language
en
Licence
Funders
National Institutes of Health (P01AG030128)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review